Semaglutide and Hypothyroidism: What Thyroid Patients Need to Know

*This article is for informational purposes only. It does not constitute medical advice. Compounded semaglutide is not FDA-approved. Consult a licensed healthcare provider before starting any medication or making changes to your treatment plan. Individual results vary.*

---

You have been taking levothyroxine for years. Your thyroid labs look fine. Your provider says your hypothyroidism is "well-managed." And yet losing weight still feels harder than it should be.

You are not imagining it. Thyroid conditions genuinely complicate weight management, even when your TSH sits in the normal range. That is one reason so many people with hypothyroidism are now asking whether GLP-1 medications like semaglutide could help.

The short answer is that hypothyroidism is not a contraindication to semaglutide. But there are real considerations you and your provider need to discuss before you start. This article walks through all of them.

---

What Hypothyroidism Does to Your Weight

The thyroid gland regulates metabolism through the hormones it produces, primarily T4 (thyroxine) and T3 (triiodothyronine). When the thyroid is underactive, it produces less of these hormones. The result is a slower metabolism, which means your body burns fewer calories at rest.

Hypothyroidism affects roughly 20 million Americans, with Hashimoto's thyroiditis (an autoimmune condition) being the most common underlying cause. The classic symptoms include fatigue, cold intolerance, constipation, and weight gain that seems disproportionate to caloric intake.

Here is what makes weight management especially frustrating for thyroid patients: even when hypothyroidism is treated and TSH levels are normalized, metabolism does not always return fully to its pre-disease baseline. Research has found that many adequately treated hypothyroid patients continue to have a slightly lower metabolic rate compared to people without thyroid disease. They also report higher rates of obesity and difficulty with weight loss despite good lab values.

This is not a personal failing. It is a physiological reality that makes standard diet and exercise advice less effective for this population.

---

How GLP-1 Medications Work

Semaglutide belongs to a class of medications called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It signals the brain to reduce appetite, tells the pancreas to release insulin, and slows the rate at which food moves through the stomach.

Prescription-strength semaglutide (at the 2.4 mg weekly dose used for weight management) was studied in the STEP 1 trial, a large randomized controlled trial published in the New England Journal of Medicine in 2021. Participants taking semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. (PMID: 33567185, Wilding JPH et al., NEJM 2021)

Compounded semaglutide, prepared by licensed 503A compounding pharmacies based on individual prescriptions from licensed providers, is made with the same active pharmaceutical ingredient (API). Compounded semaglutide is not FDA-approved and is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products.

The weight loss mechanism - appetite suppression and reduced caloric intake - works independently of thyroid status. That is an important starting point for understanding why thyroid patients can, in many cases, use this class of medications.

---

The Critical Distinction: Hypothyroidism vs. Medullary Thyroid Cancer

Before going further, one distinction deserves its own section because confusion about it is common and potentially harmful.

Semaglutide carries an FDA black box warning related to thyroid C-cell tumors. This warning was triggered by rodent studies in which GLP-1 receptor agonists caused dose-dependent thyroid C-cell tumors. Because of this finding, semaglutide and all GLP-1 receptor agonists are contraindicated for people with:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Medullary thyroid carcinoma is a rare cancer of thyroid C-cells (the cells that produce calcitonin). It accounts for only 2 to 3 percent of all thyroid cancers diagnosed annually in the United States. Hypothyroidism, on the other hand, is a disease of the follicular cells that produce thyroid hormone. These are different cell types, different conditions, and different risk profiles.

If your thyroid history involves Hashimoto's thyroiditis, Graves' disease, or standard hypothyroidism on levothyroxine, you do not fall into the contraindicated category. The black box warning is not directed at you.

This is a distinction your provider can confirm after reviewing your personal history.

---

Does Hypothyroidism Affect How Well Semaglutide Works?

This is one of the most practical questions thyroid patients ask. The evidence is still emerging, but early research is reassuring.

A 2025 study published in PLOS ONE followed individuals with well-controlled hypothyroidism (on stable levothyroxine doses) who used liraglutide, another GLP-1 receptor agonist with a similar mechanism to semaglutide. Researchers found that these patients achieved clinically meaningful weight and body composition improvements comparable to results seen in people without thyroid disease. (PMID: 40934243, Chukir T et al., PLOS ONE 2025)

A retrospective analysis published in the Journal of Medical Life in 2025 examined oral semaglutide use in patients with both hypothyroidism and type 2 diabetes. The study found meaningful reductions in metabolic syndrome components, including body weight, waist circumference, and fasting glucose, in the hypothyroid population. (PMID: 41635458, Tilici DM et al., J Med Life 2025)

A follow-up comparative study published in 2026 looked specifically at six-month outcomes in patients on both oral semaglutide and levothyroxine, examining cardiometabolic and thyroid parameters together. The results supported the use of GLP-1 therapy in this population, while also highlighting the importance of TSH monitoring during treatment. (PMID: 41873990, Tilici DM et al., Epidemiologia 2026)

In short, having hypothyroidism does not appear to prevent GLP-1 medications from working. Thyroid patients in current studies are achieving weight loss with this class of drugs.

---

The Levothyroxine Interaction You Need to Know About

This is where careful attention is genuinely warranted. GLP-1 medications slow gastric emptying, which means food and medications move through your digestive system more slowly than usual.

Levothyroxine (Synthroid, Tirosint, and generic equivalents) has a well-known sensitivity to timing and absorption. It is typically taken fasted, 30 to 60 minutes before breakfast, for a specific reason: food, especially high-calcium and high-fiber foods, significantly reduces its absorption. Many medications and supplements can also interfere with levothyroxine absorption.

Slowed gastric emptying from a GLP-1 medication adds a new variable. If digestion is slower, the timing relationship between levothyroxine and food becomes less predictable, potentially leading to variable absorption.

A 2026 study published in the Journal of Clinical Endocrinology and Metabolism examined patterns of TSH testing in patients who started GLP-1 receptor agonists while already on levothyroxine. Researchers found a statistically significant number of these patients had TSH changes after initiating GLP-1 therapy, with some patients requiring levothyroxine dose adjustments. (PMID: 41902399, Chen Y et al., J Clin Endocrinol Metab 2026)

A 2025 case report published in Endocrinology, Diabetes and Metabolism Case Reports documented a case of iatrogenic thyrotoxicosis in a patient on levothyroxine who started semaglutide. The proposed mechanism was altered levothyroxine absorption secondary to changed gastric motility. The condition resolved after levothyroxine dose adjustment. (PMID: 40638337, Barnett MJL, Endocrinol Diabetes Metab Case Rep 2025)

That case report represents a rare outcome, not a typical one. But it illustrates why thyroid monitoring is not optional for this patient group.

What Practically Matters for You

If you take levothyroxine and are starting a GLP-1 medication, these steps matter:

Continue taking levothyroxine fasted. Keep your standard morning routine. Take your levothyroxine dose at least 30 minutes before eating, as you normally would. Do not change your timing protocol without guidance from your provider.

Get your TSH checked 6 to 12 weeks after starting GLP-1 therapy. This is the window when absorption changes typically become apparent. Your provider may want to check sooner depending on your history.

Expect possible dose adjustments as you lose weight. Levothyroxine dosing is often calibrated to body weight. As you lose weight on semaglutide, your levothyroxine requirement may decrease. A dose that was appropriate at 215 pounds may be too high at 185 pounds, producing symptoms of over-replacement (palpitations, anxiety, feeling overheated).

Tell your prescribing provider exactly which medications you take. This includes over-the-counter supplements. Calcium, iron, magnesium, and even some antacids can interfere with levothyroxine absorption and should be taken several hours apart from your thyroid medication.

---

What Good Monitoring Looks Like

For a person with well-controlled hypothyroidism starting a GLP-1 medication, a reasonable monitoring framework includes:

A baseline TSH check before starting therapy to confirm where your thyroid levels stand. A TSH check at 6 to 12 weeks after initiating GLP-1 therapy to catch any absorption-related changes early. Ongoing TSH monitoring at your usual intervals (typically every 6 to 12 months once stable), with additional checks if you lose more than 10 to 15 percent of your body weight, develop new symptoms, or change your levothyroxine dose.

Your endocrinologist or primary care provider can help you build this monitoring plan. If you have not seen your thyroid prescriber recently, this is a good time for that visit.

---

Who Should Not Use Semaglutide

While hypothyroidism alone is not a contraindication, there are situations where semaglutide is not appropriate:

Personal or family history of medullary thyroid carcinoma (MTC). As described above, this is an absolute contraindication for all GLP-1 receptor agonists.

Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Same absolute contraindication.

History of pancreatitis. GLP-1 medications are associated with a risk of pancreatitis and are generally avoided in patients with a prior episode.

Pregnancy. GLP-1 medications are not recommended during pregnancy.

Certain kidney, heart, or gastrointestinal conditions. Your provider will review your full history.

If you have autoimmune thyroid disease (Hashimoto's or Graves') with no history of MTC or MEN2, those autoimmune conditions themselves do not prohibit semaglutide use. Your provider is the appropriate person to make a final determination after reviewing your complete medical history.

---

Talking to Your Provider: Questions to Ask

Preparation makes the most of the time you have with your healthcare team. When discussing whether a GLP-1 medication is right for you, consider asking:

Does my thyroid history include anything that would make semaglutide contraindicated for me specifically?

How often should I check my TSH while on this medication?

At what point should I expect to reassess my levothyroxine dose?

What symptoms should prompt me to call your office between scheduled appointments?

Are there any interactions between GLP-1 medications and my other thyroid supplements or medications?

Your provider can give you personalized answers that apply to your specific history and current labs.

---

The Bottom Line

Having hypothyroidism does not automatically disqualify you from using GLP-1 medications like semaglutide. The thyroid contraindication in the prescribing information applies to medullary thyroid cancer and MEN2 syndrome, not to common hypothyroidism.

Early research suggests thyroid patients can achieve meaningful weight loss outcomes with GLP-1 therapy. The most important clinical consideration is levothyroxine absorption: GLP-1 medications slow gastric emptying, which can affect thyroid hormone levels over time. Regular TSH monitoring after starting therapy, and thoughtful dose adjustments as your weight changes, are the practical safeguards that make this combination manageable.

The best next step is a conversation with your healthcare provider, who can review your thyroid history, current medications, and overall health to determine whether a GLP-1 program is right for you.

Ready to explore your options? Check your eligibility for Prescriva's medically supervised weight management program and get started with a provider consultation.

---

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.

Compounding Disclaimer: Compounded semaglutide is not an FDA-approved medication. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products (Ozempic, Wegovy, or Rybelsus).

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Prescriva LLC, doing business as Prescriva is a management services organization and does not practice medicine or make clinical decisions.

Brand Disclaimer: Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva is not affiliated with, endorsed by, or sponsored by these companies.

---

Sources

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021 Mar 18. PMID: 33567185

1. Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine. 2023 Dec 14. PMID: 37952131

1. Chukir T, et al. "Weight and body composition outcomes with liraglutide in individuals with well-treated hypothyroidism." PLOS ONE. 2025. PMID: 40934243

1. Tilici DM, et al. "Modulation of metabolic syndrome components by oral semaglutide in hypothyroid-T2DM patients: a retrospective analysis." Journal of Medical Life. 2025 Dec. PMID: 41635458

1. Tilici DM, et al. "Combined Treatment of Type 2 Diabetes and Hypothyroidism: Impact of Oral Semaglutide and Levothyroxine on Cardiometabolic and Thyroid Parameters: A 6-Month Comparative Study." Epidemiologia (Basel). 2026 Mar 4. PMID: 41873990

1. Chen Y, et al. "Patterns of Thyroid-Stimulating Hormone Test After GLP-1 RAs Initiation in Patients on Levothyroxine." Journal of Clinical Endocrinology and Metabolism. 2026 Mar 27. PMID: 41902399

1. Barnett MJL. "Semaglutide therapy and iatrogenic thyrotoxicosis." Endocrinology, Diabetes and Metabolism Case Reports. 2025 Jul 1. PMID: 40638337